Sun, Michael
Niaz, Muhammad Junaid
Niaz, Muhammad Obaid
Tagawa, Scott T. http://orcid.org/0000-0003-2777-8587
Article History
Accepted: 12 February 2021
First Online: 29 March 2021
Declarations
:
: Michael Sun, Muhammad Junaid Niaz, and Muhammad Obaid Niaz declare no conflict of interest. Weill Cornell Medicine has received research funding for trials led by Scott T. Tagawa from Novartis/Advanced Accelerator Applications, Bayer, POINT Biopharma, Amgen, Atlab, Progenics, Pfizer, Clovis Oncology, Janssen, Seattle Genetics, Immunomedics, Ambrx, Inovio, Sanofi, Merck, Karyopharm, AbbVie, AstraZeneca, and Bristol-Myers Squibb; and he has received compensation for service as a consultant from Novartis/Advanced Accelerator Applications, Bayer, Blue Earth Diagnostics, POINT Biopharma, Amgen, Pfizer, QED, Clovis Oncology, Janssen, Seattle Genetics, Immunomedics, Ambrx, Sanofi, Karyopharm, and AbbVie.
: This article does not contain any studies with human or animal subjects performed by the authors.